Estimations des analystes de Wall Street pour Fate Therapeutics, Inc. (FATE): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 16 |
| Conserver | 13 |
| Vente | 2 |
| Vente forte | 0 |
| Analystes au total | 31 |
| Note moyenne (1-5) | 0.45 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.27 | ||
| 2026-08-13 | $-0.25 | $-0.25 | +1.4% |
| 2026-05-13 | $-0.26 | $-0.29 | +10.3% |
| 2026-02-26 | $-0.27 | $-0.27 | +0.0% |
| 2025-11-13 | $-0.27 | $-0.29 | +6.9% |
| 2025-08-12 | $-0.29 | $-0.35 | +17.1% |
| 2025-05-13 | $-0.32 | $-0.39 | +17.9% |
| 2025-03-05 | $-0.44 | $-0.44 | +0.0% |
Ratios de valorisation
| Prix / Valeur comptable | 1.96 |
| EV / EBITDA | -2.84 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $4.4M | $4.1M | $4.7M | $10.7M | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | $6.6M |
| Coût des Ventes | $26.5M | $34.4M | $56.0M | 0 | $125.6M | $5.8M | $13.8M | $157.2M | $118.5M | $12.9M |
| Marge Brute | -$22.1M | -$30.3M | -$51.3M | $10.7M | -$94.2M | $50.0M | $82.5M | -$93.7M | -$104.9M | -$6.3M |
| R&D | $26.5M | $34.4M | $56.0M | $87.8M | $125.6M | $215.5M | $320.5M | $172.6M | $135.0M | $107.8M |
| Frais Généraux | $9.9M | $11.9M | $15.8M | $23.6M | $33.9M | $57.3M | $84.2M | $96.9M | $90.6M | $46.5M |
| Charges Opérationnelles | $36.4M | $46.2M | $71.8M | $111.4M | $33.9M | $267.0M | $390.9M | $96.9M | $105.4M | $141.4M |
| Résultat Opérationnel | -$32.0M | -$42.1M | -$67.1M | -$100.7M | -$128.1M | -$217.0M | -$308.4M | -$190.5M | -$210.3M | -$147.7M |
| EBITDA | -$30.9M | -$40.7M | -$63.7M | -$94.2M | -$125.0M | -$206.3M | -$268.0M | -$142.6M | -$176.6M | -$127.0M |
| Charges d'Intérêt | $1.6M | $1.3M | $1.7M | $1.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Avant Impôts | -$33.5M | -$43.0M | -$66.6M | -$98.1M | -$173.4M | -$212.2M | -$281.7M | -$160.9M | -$186.3M | -$136.3M |
| Impôts | 0 | $297000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Net | -$33.5M | -$43.0M | -$66.6M | -$98.1M | -$173.4M | -$212.2M | -$281.7M | -$160.9M | -$186.3M | -$136.3M |
| BPA | $-1.05 | $-1.02 | $-1.19 | $-1.43 | $-2.10 | $-2.24 | $-2.91 | $-1.64 | $-1.64 | $-1.15 |
| BPA Dilué | $-1.05 | $-1.02 | $-1.19 | $-1.43 | $-2.10 | $-2.24 | $-2.91 | $-1.64 | $-1.64 | $-1.15 |
| Actions en Circulation (Diluées) | $31.8M | $42.0M | $56.2M | $68.2M | $82.4M | $94.7M | $96.8M | $98.4M | $113.7M | $118.8M |
Prix
| Prix | $2.44 |
| Capitalisation | $284M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ABOS · ALEC · CRBP · INO · MOLN · NKTX · PEPG
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de FATE: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions